Dr. Sarah Moseley is the National Field Director in the Medical Affairs Division at GRAIL Inc. Dr. Moseley leads a team of MSLs and Managed Care MSLs in support of broad use of GRAIL’s multi-cancer early detection Galleri test in clinical practice and pipeline products.

Dr. Moseley has held a number of leadership positions in pharma and diagnostic companies in both R&D and Medical Affairs including Roche Diagnostics where she held a number of roles including leading the National Medical Field Team in support of development and implementation of precision diagnostic devices in Genomics & Oncology, CoDx, Virology, Microbiology, Women’s Health and Donor Screening. Dr. Moseley was accountable for the medical launch of numerous paradigm shifting IVD solutions including HPV primary screening in cervical cancer; the first FDA approved Companion Diagnostic test that formed the blueprint for CoDx approval, and the first FDA approved liquid biopsy assay for selecting lung cancer patients for targeted therapies. Dr. Moseley also served as Director for Medical Diagnostics Oncology at AstraZeneca. Her primary focus was overcoming the barriers to adoption and implementation of system-wide quality Precision Medicine solutions in US healthcare systems to provide more patients access to the right, potentially life saving therapeutics. Sarah also served in the R&D Molecular Oncology Division of Genentech.

Dr. Moseley earned a BSc in Biochemistry from the University of East Anglia, Norwich UK; a doctorate in Molecular, Cell and Developmental Biology from the University of California, Santa Cruz and completed her Postdoctoral Fellowship at the University of California, San Francisco. Sarah is originally from the UK but has lived in the US for over 25 years, most of that time in the Bay Area. Sarah enjoys downhill mountain biking, surfing and riding sports motorcycles